Khursheed Anwer

Khursheed Anwer

Company: Celsion

Job title: Chief Scientific Officer & Executive Vice President


Group Panel Discussion: Side Effects – Mitigating Against Hypotension + Fever With Immune-Stimulating Agents (NK Cell Engagers, PD-1s, Cytokines, T-Cell Engagers) = Cytokine Release Syndrome (CRS)? 11:30 am

What are the differences between the symtoms and the tests Uncover the implications for patients and regulatory bodies Examine the Implications for CAR-T Could this redefine CRS?Read more

day: Day Two

A Non-Viral Gene Therapy Approach to IL-12 Delivery for The Treatment of Cancer 8:30 am

Understand how local delivery of IL-12 without significant systemic toxicity is feasible with a non-viral gene therapy approach that involves administration of an IL-12 plasmid with a synthetic DNA delivery system (GEN-1) Learn how weekly administration of GEN-1 into peritoneal cavity yields durable increases in IL-12 and IFN-g and the treatment is tolerable upon repeat…Read more

day: Day Two

Breakfast Panel: What Do We Know & Where Do We Want to Go? 7:40 am

How can we learn from successes and shortfalls of the previous cytokine era Where have the current engineering strategies taken us? Reflecting back on what we learned in the previous cytokine era Assessing the latest clinical work with lesser known/used cytokines Considerations for moving current promising pre-clinical data into the clinic Combinations? Where is there…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.